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Abstract
Background: Ayahuasca is a psychoactive ethnobotanical concoction that has been used for decades by indigenous groups of the Northwestern Amazon and 
by syncretic religious organizations for ritual and therapeutic purposes. In the last two decades, it is being used worldwide in evolving practices. Ayahuasca 
seem to therapeutic effects, but controlled studies are lacking. Moreover, its safety and toxicity are not completely understood. Objectives: To present an 
overview of the effects of ayahuasca based on the most recent human studies. Methods: Narrative review. Results: Ayahuasca administration in controlled 
settings appears to be safe from a subjective and physiological perspective, with few adverse reactions being reported. More frequent adverse reactions occur 
in non-controlled settings. Prolonged psychotic reactions are rare and seem to occur especially in susceptible individuals. Ayahuasca showed antidepressive, 
anxiolytic, and antiaddictive effects in animal models, observational studies, and in open-label and controlled studies. Discussion: Ayahuasca administration 
in controlled settings appear to be safe. Moreover, ayahuasca seem to have therapeutic effects for treatment-resistant psychiatric disorders that should be 
further investigated in randomized controlled clinical trials. However, medical complications and cases of prolonged psychotic reactions have been reported, 
and people with personal or family history of psychotic disorders should avoid ayahuasca intake. 
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Introduction
Ayahuasca (from the Quechua Aya – “soul”, “dead spirit”; and Waska – 
“rope”, “vine”) is a natural psychoactive concoction used for centuries 
by indigenous groups from Northwestern Amazonian countries 
such as Brazil, Peru, Colombia and Ecuador for ritual, religious, 
and therapeutic purposes1. Ayahuasca has dozens of indigenous 
names, such as Yajé, Kamarampi and Huni, and is also used by the 
nonindigenous mestizo populations of these countries. Syncretic 
religious organizations that originated in Brazil in the 1930-1960’s 
such as the Santo Daime, Barquinha, and União do Vegetal (UDV) 
use ayahuasca as a sacrament, where is known as daime, vegetal or 
hoasca. In the last 25 years, these groups spread from Brazil to Europe, 
the United States, Asia and Africa2,3.
Botany, chemistry and mechanism of action
The main ingredient of ayahuasca is the vine Banisteriopsis caapi 
(Figure 1), which contains β-carbolines alkaloids such as harmine, 
tetrahydroharmine (THH) and harmaline (Figure 2)4. The vine 
is commonly used in combination with lots of different plants 
depending on the purpose of the ceremony1,2,4. In the Western 
world, ayahuasca is known to be the mixture of the vine B. caapi 
with the leaves of Psychotria viridis (Figure 1) or from the vine 
Diplopterys cabrerana, that contain the tryptamine hallucinogen 
dimethyltryptamine (DMT) (Figure 2). This probably happened 
because of the international expansion of ayahuasca by the Brazilian 
ayahuasca churches and also by South American shamans4. The 
beverage is usually prepared by the prolonged decoction of these 
plants and has a brownish color (Figure 1).
DMT is not active when ingested alone because it is metabolized 
in the gastrointestinal tract and in the liver by monoamine oxidase A 
(MAO-A). However, the β-carbolines in the vine reversibly inhibit 
MAO-A and allow DMT to reach the Central Nervous System4-6. 
The main mechanism of action of DMT appears to partial agonism 
on serotonergic 2A (5-HT2A) receptors expressed on layer V cortical 
neurons, a process that also seems to involve metabotropic glutamate 
receptors (mGluR)7,8. DMT is an endogenous compound, although 
its physiological functions are not known9,10. There is some evidence 
that endogenous DMT could act as a neurotransmitter on sigma 
receptors11,12, but human studies suggest that the psychoactive 
effects of classic/serotonergic hallucinogens such as lysergic acid 
diethylamide (LSD), psilocybin and DMT are mainly mediated by 
the 5-HT2A receptor8,13-15.
Figure 2. Chemical structures of the ayahuasca alkaloids: dimethyltrypta-
mine (DMT); harmine; tetrahydroharmine (THH); and harmaline.
Figure 1. Ayahuasca preparation (from right to left): Banisteriopsis caapi; 
Psychotria viridis; ayahuasca decoction; ayahuasca prepared and bottled. 
Photographs by Rafael G. dos Santos.
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photon emission computed tomography (SPECT), and structural 
and functional magnetic resonance imaging (MRI and fMRI, 
respectively).21,25,26 Results from EEG studies are inconsistent and 
sometimes conflicting (Table 2)26. For instance, although reduced 
power in the alpha, delta and theta bands was observed in some 
studies14,27-29, it was not reported in others19,24. Likewise, increased 
power in the beta band was reported in some studies19,24,27 but not 
in others14,28,29. Increased gamma power was not reported in most 
studies26,29. Regarding other serotonergic hallucinogens, reductions in 
alpha power were also observed in studies with psilocybin and LSD, 
an effect that seem to underlie the visual effects of these compounds 
through their agonism at cortical 5-HT2A receptors14,26,30,31. 
In the last 10 years, the neural basis of the effects of ayahuasca 
have been investigated using SPECT, MRI and fMRI (Table 2)21,25,26. 
A SPECT study of acute administration with healthy volunteers 
showed that ayahuasca increased bilateral activation of the anterior 
insula/inferior frontal gyrus, right hemisphere activation of the 
anterior cingulate cortex (ACC) and frontomedial cortex, and left 
hemisphere activation of the amygdala and parahippocampal gyrus32. 
These brain areas are involved in the modulation of emotions, 
internal feelings and sensations, perception and self-awareness. An 
fMRI study using an imagery task showed that ayahuasca not only 
increased activation of the parahippocampal and frontopolar cortices, 
but also of the cuneus and lingual gyrus and retrosplenial cortex20. 
Interestingly, during the imagery task ayahuasca increased activation 
of the primary visual area in a manner similar to the activation 
levels of seeing a natural image with the eyes open. This effect may 
be one explanation to the so vivid and “real” effects of the ayahuasca 
experience. Moreover, a significant correlation was observed between 
cortical area BA17 activation and BPRS (Brief Psychiatric Ratings 
Scale) data. Finally, ayahuasca reversed fronto-occipital connectivity, 
what seems to mean that the visions induced by ayahuasca may be 
initiated in the primary visual cortex. The difference between this 
study and the SPECT study, where visual areas were not activated, 
may be determined by the task since in the fMRI study subjects were 
instructed to do tasks related with visual stimulation and/or imagery. 
Table 1. Subjective and physiological effects of ayahuasca
Positive subjective effects (acute)16,18-21
Introspection
Serenity
Memories with autobiographical content
Positive mood, affect and wellbeing
Altered perception of colors and sounds (synesthesia)
Mystical/religious experiences
Negative subjective effects (acute/subacute)16,18,20-22
Anxiety, panic, and fear
Psychotic symptoms (less common)
Negative subjective effects (prolonged)23,59
Psychotic reactions (rare)
Physiological effects (acute)5,14,18,19,21,24
Moderate increases in blood pressure and heart rate
Mydriasis 
Increases in body temperature
Increases in prolactin, cortisol, and growth hormone secretion 
Increases in natural killer cells levels
Decreases on CD3 and CD4 lymphocyte levels
Subjective effects
The subjective effects of ayahuasca (and other hallucinogens) are 
difficult to describe and measure16,17. Experimental studies with 
healthy volunteers and longitudinal studies with experienced 
ayahuasca users show that these subjective effects include increases 
in introspection, serenity, and in experiencing memories with 
autobiographical content, positive mood, affect, and wellbeing, 
altered perception of colors and sounds often accompanied by 
synesthesia, and also mystical-like and religious experiences (Table 
1)16,18-21. In the clinical studies, the variable that measure volition (or 
the capacity to interact with the environment) is only slightly affected 
and subjects usually rate the experience as “good effects” and “liking”, 
while the ratings on “drunken” and “bad effects” are the variables 
with the lower scores5,19. Administration of two consecutive doses 
of ayahuasca four hours apart does not seem to induce tolerance or 
sensitization to the psychological effects19. Dysphoric reaction are 
less frequent and my include anxiety, fear, and psychotomimetic 
symptoms, but these effects are generally transient and usually do not 
need medical intervention16,18,20,21. Prolonged dysphoric or psychotic 
reactions in controlled contexts (experimental or ritual) are rare and 
seem to occur mostly among individuals with a personal or family 
psychiatric history, although cases where there was no personal of 
family antecedent have also been reported (Table 1)22,23.
Physiological effects
Experimental studies with healthy volunteers showed that 
administration of a single ayahuasca dose induced moderate and 
transient (less than 24 hours) increases in blood pressure and 
heart rate, on prolactin, cortisol, and growth hormone (GH) levels, 
on pupil size and body temperature, and in natural killer (NK) 
cells levels. Ayahuasca administration also induced transitory 
decreases on lymphocyte (CD3 and CD4) levels (Table 1)5,14,18,19,21,24. 
Two consecutive doses of ayahuasca did not induce tolerance or 
sensitization for most physiological variables, but a trend to lower 
cardiovascular activation was observed, and tolerance was reported 
to GH secretion19.
Neurophysiological and neuroimaging studies
The effects of ayahuasca on brain dynamics were assessed in 
healthy volunteers using electroencephalography (EEG), single-
Table 2. Effects of ayahuasca on the human brain
EEG (acute)14,19,24,26-29
Reduced power in the alpha, delta and theta bands
Increased power in the beta and gamma bands
Neuroimaging (acute)20,32,33
Increased activation of frontal and limbic areas (parahippocampal gyrus, insula, 
amygdala, visual and frontal cortices, ACC) (SPECT, fMRI)
Increased activation of the primary visual area during an imagery task (fMRI)
Decreased activation of key hubs of the DMN (PCC, mPFC, precuneus) (fMRI)
Decreased functional connectivity within the PCC/precuneus (fMRI)
Neuroimaging (long-term)34
Cortical thickening in precentral gyrus and ACC (CT)
Cortical thinning in the mesotemporal and inferior frontal gyri, precuneus, 
superior frontal gyrus, PCC, and superior occipital gyrus (CT)
ACC: anterior cingulate cortex; CT: cortical thickness; DMN: default mode network; 
EEG: electroencephalography; fMRI: functional magnetic resonance imaging; mPFC: medial 
prefrontal cortex; PCC: posterior cingulate cortex; SPECT: single-photon emission computed 
tomography.
A resting-state fMRI study showed that ayahuasca decreased 
activation of key hubs of the default mode network (DMN), including 
the posterior cingulate (PCC) and the medial prefrontal cortices 
and the precuneus33. Furthermore, ayahuasca decreased functional 
connectivity within the PCC/precuneus. Studies with psilocybin and 
LSD also show that these drugs produce their effects by modulating 
brain structures involved in emotional processing and in memory 
and self-awareness, such as the parahippocampal gyrus, visual and 
frontal cortices, ACC and PCC, insula and amygdala15,21,25,26,30,31.
An MRI study assessing cortical thickness in long-term ritual 
ayahuasca users showed that regular use (average 5.3 years, range 
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2-13 years) was associated with cortical thinning in the mesotemporal 
and inferior frontal gyri, precuneus, superior frontal gyrus, PCC 
and superior occipital gyrus. On the other hand, increased cortical 
thickening was observed in precentral gyrus and ACC34. Importantly, 
these structural characteristics were not associated with increased 
psychopathology among ayahuasca users. Moreover, cortical 
thinning in the PCC was inversely correlated to age of onset and 
intensity of prior ayahuasca use and to core on a “self-transcendence” 
scale. Ayahuasca users also scored better in some neuropsychological 
tasks related with executive functions compared to controls that 
were were matched in fluid and verbal IQ, age and gender, among 
others variables.
Therapeutic potentials
Ayahuasca has been traditionally used by indigenous groups 
and mestizo populations for getting in contact with the sacred or 
supernatural world, for political and artistic purposes, and also 
for healing1,2,35. Nevertheless, the worldview and culture of these 
populations, and the way they understand and use ayahuasca, are 
often different from those of nonindigenous populations. Thus, 
it is not always possible to translate a therapeutic effect described 
in a traditional context to the concepts of diseases that are shared 
in the nonindigenous culture. However, over the last 30 years, an 
increasing number of anecdotal reports and experimental evidence 
has accumulated suggesting that ayahuasca may have therapeutic 
potentials in the treatment of difficult-to-treat psychiatric disorders 
such as drug dependence and anxiety and mood disorders21,25,36.
Preclinical studies and observational studies of ayahuasca users 
suggest that ayahuasca has anxiolytic, antidepressive and antiaddictive 
effects (Table 3)21,34,37-40. Regarding anxiolytic and antidepressive 
effects in humans, a double-blind, placebo-controlled studies with 
nine experienced ayahuasca users showed that a single ayahuasca dose 
was associated with less panic symptoms and reduced hopelessness41. 
An open-label study by our group showed that a single ayahuasca 
dose was associated with rapid and sustained reductions in anxiety 
and depressive symptoms in 17 patients with treatment-resistant 
major depressive disorder42. The anxiolytic and antidepressive effects 
were observed already in the first hours after ayahuasca intake and 
remained significant for 21 days. Moreover, SPECT imaging showed 
that ayahuasca administration was associated with increased blood 
perfusion in the left nucleus accumbens, right insula, and left 
subgenual area, brain regions associated with emotional processing 
and the therapeutic effects of traditional antidepressants. These 
results were partially replicated by our group in a recent parallel 
arm, double-blind, randomized, placebo-controlled trial in which 
35 patients with treatment-resistant major depression received 
a single dose of ayahuasca or placebo43. Compared with patients 
that received placebo, patients that received ayahuasca had lower 
depressive symptoms seven days after drug administration. These 
results are in agreement with recent studies showing anxiolytic 
and antidepressive effects of serotonergic hallucinogens such as 
psilocybin and LSD36,44-47. Regarding antiaddictive effects in humans, 
although there are no controlled trials, non-controlled studies in 
therapeutic and ritual settings suggest that ayahuasca use may have 
antiaddictive effects48,49. Moreover, studies with psilocybin and LSD 
also suggest that hallucinogenic compounds that act as 5-HT2A 
agonists have antiaddictive effects36,50,51.
Table 3. Main therapeutic potentials of ayahuasca








Classic or serotonergic hallucinogens including LSD, psilocybin, 
mescaline and DMT are considered drugs with low physiological 
toxicity that can be safely administered in controlled settings, 
including both ritual and experimental/clinical contexts8,17,25,26,36,52,53. 
Recent human studies involving acute administration of LSD 
and psilocybin to healthy volunteers and to patients with drug 
dependence or anxiety and mood disorders show that these drugs 
induce significant subjective and physiological effects that are 
transient, well tolerated, and apparently associated with therapeutic 
effects13,15,30,31,44,47,50,51,53. 
In the specific case of ayahuasca, in the last 30 years a 
few observational studies of long-term ayahuasca users were 
conducted, and their results suggest that ritual use of this substance 
is not associated with increased psychopathology or cognitive 
deficits21,34,37,38,54-57. Moreover, a clinical evaluation of long-term (at 
least 10 years) ritual ayahuasca users, including blood analysis and 
assessments of cardiovascular, endocrine, immunological, hepatic 
and renal function, did not show any clinically relevant findings 
compared to a control groups without ayahuasca use58. However, 
in these studies the samples are mostly composed of experienced 
users well adapted to the effects of ayahuasca and that are long-term 
members of organized religious groups. Thus, these participants 
may have specific characteristics that could limit the generalization 
of the results. Moreover, although psychiatric complications such as 
anxiety and psychotic reactions associated with ritual ayahuasca are 
rare, they may occur, especially among vulnerable individuals21-23. In 
the ritual contexts of ayahuasca use, individuals with a personal or 
family history of psychotic illness or that are currently with psychotic 
symptoms are generally not allowed to use ayahuasca or are advised 
that they should avoid it23,59. This could explain at least in part the low 
incidence of psychotic reactions among ritual ayahuasca users, and 
show that individuals with a personal or family history of psychotic 
illness or nonpsychotic mania should avoid ayahuasca use23,59.
Regarding experimental and clinical studies of acute 
ayahuasca administration, several studies performed in the last 
15 years with both healthy volunteers and clinical populations 
consistently show that ayahuasca can be safely administered in the 
laboratory5,14,18-21,24,27-29,32,33,36,41-43. The most common adverse reactions 
to ayahuasca are nausea and vomiting, which is often accompanied 
by other somatic-dysphoric effects such as feeling heat and/or 
cold and gastrointestinal discomfort (Table 4)18,19,24,42,43. In ritual 
contexts, vomiting is not interpreted as negative, being understood 
as a cleansing process2,16,35. In early laboratory studies using freeze-
dried ayahuasca, vomiting was observed in four of 53 ayahuasca 
administrations (7.5%)5,18,60. In a subsequent study by the same group 
involving the administration of two consecutive ayahuasca doses 
four hours apart, only nine of the 17 enrolled volunteers completed 
the trial, and five of them were excluded from the trial due to 
vomiting (self-induced in one case), since it was a pharmacokinetic 
study19. In our open-label study involving the administration of a 
single ayahuasca dose to 17 patients with treatment-resistant major 
depressive disorder, vomiting was the only adverse effect reported and 
occurred in 47% of the volunteers42. In our subsequent randomized 
controlled trial, the most common adverse reaction were nausea 
(71%), vomiting (57%), transient anxiety (50%), transient headache 
(42%), and restlessness (50%)43.
As discussed above in the topic on the physiological effects 
of ayahuasca, acute administration of this substance may induce 
transient and moderate increases in blood pressure and heart rate, 
in both healthy volunteers and depressed patients5,18,19,42,60. However, 
since the cardiovascular effects of ayahuasca were only assessed 
in studies of acute administration to young volunteers without 
cardiovascular complications, the long-term effects of continuous 
ayahuasca intake and its use by older individuals or by people with 
hypertension or other cardiac disorders are not known. Although 
the above-mentioned study among experienced ayahuasca user did 
not find evidence of increased incidence of cardiovascular diseases in 
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this group compared to the control group, seven electrocardiographic 
alterations were found in the ayahuasca group (one case of right 
branch bundle block, one of left branch bundle block, one of 
diffuse ventricular repolarization disturbance, and four of sinusal 
bradycardia), while among the controls there was only a single case 
of sinusal bradycardia58. Moreover, although these alterations were 
not clinically relevant, this is only a single study, and a recent study by 
our group showed that ayahuasca altered some structural parameters 
of the rat aorta61. Thus, more studies are needed to better clarify the 
cardiovascular effects of ayahuasca, especially the long-term effects.
Although ayahuasca administration in the experimental or 
clinical setting may induce anxiety and psychotic/psychotomimetic or 
dissociative symptoms, these effects are usually mild and short-lived, 
and most participants consider the experience pleasant18,20,21,42,43,60. 
Its important to highlight that individuals with a personal or family 
history of psychotic illness or nonpsychotic mania are usually not 
enrolled in these studies, which could explain the absence of reports 
of prolonged dysphoric or psychotic reaction in the experimental 
and clinical settings5,14,18-21,23,24,27-29,32,33,36,41-43,60. These results are in 
line with experimental and clinical studies with other serotonergic 
hallucinogens such as LSD and psilocybin13,15,30,31,36,44-47,50-53.
Limitations of the studies 
Although the number of observational studies of long-term ayahuasca 
users and of studies involving ayahuasca administration to both 
healthy volunteers and clinical populations has increased over the last 
years, most of them share similar limitations that render their results 
preliminary and inconsistent. For instance, most studies of acute and 
subacute effects, both uncontrolled and controlled, had small sample 
sizes. Long-term studies usually had bigger samples, but some studies 
also had small samples. Moreover, several studies were open-label, 
observational, or had no control groups. Thus, it is difficult to affirm 
that ayahuasca had a causal role in the observed effects. In several 
studies where multiple comparisons were performed, there was no 
statistical correction for this, which could inflate false positive results 
by reporting variables that show positive results even when a large 
number of variables exist for small sample sizes. Another important 
limitation is that some of the subjective effects of ayahuasca were 
measured with questionnaires that did not have their psychometric 
qualities validated, which basically means that maybe they were not 
measuring what they say they were62.
Despite these important limitations, many of the results seem to 
be consistent among different studies21,25,26,36, and recent studies with 
other hallucinogenic compounds that also act as serotonin 5-HT2A 
receptor agonists, such as psilocybin and LSD, further support these 
findings8,25,26,36,53. Nevertheless, it is important to highlight the fact that 
some of these studies share the same limitations as those observed in 
ayahuasca studies, especially regarding small sample sizes and lack of 
a double-blind design31,45,50,51. Therefore, future studies should be well 
designed. What we are observing in psychedelic research in general 
and in ayahuasca research in particular is that in the one hand, there 
are several studies that have published only preliminary results but 
that do not mention their most important limitations and that are 
even popularizing these results in the media, leading both the general 
public and the scientific community to conclusions that cannot be 
achieved from the original research. On the other hand, almost none 
of the findings obtained were replicated until the present moment. 
Thus, in many review papers assertions appear citing papers with 
preliminary research as if those assertions were already confirmed. 
Studies methodically well designed, data analysis performed with 
proper statistical analysis, and the limitations completely described are 
urgent needs to improve this research field, so that we can avoid falling 
into the criticism and lack of trust from the scientific community 
regarding the psychedelic research performed in the 1950-1970’s63.  
Suggestions for future research
Besides the methodological issues commented above, there are 
other areas of ayahuasca research that could be explored. For 
instance, the antidepressive and anxiolytic effects of ayahuasca in 
patients with treatment-resistant major depressive disorder should 
be further explored in other clinical populations in randomized 
controlled trials with bigger samples and using different dosage 
schemes (multiple or repeated doses) to assess safety, tolerability, 
efficacy, and to compare to the results of single doses. Moreover, the 
antidepressive and anxiolytic effects of ayahuasca should be evaluated 
in other anxiety and mood disorders. For instance, recent studies 
with LSD and psilocybin for depression and anxiety in patients with 
life-threatening cancer reported promising results, and ayahuasca 
could also be evaluated in this clinical population44,46,47. Regarding 
drug dependence, although there is evidence from animal studies 
and from anecdotal reports and uncontrolled studies suggesting that 
ayahuasca has antiaddictive properties21,38,40,48,49,54,57, no controlled 
trials were ever performed and they are urgent needed. 
Another area that should be better investigated is related to 
the possible chemical interactions between ayahuasca and other 
compounds such as certain foods, recreational drugs, psychoactive 
plants, or medications in general. Some studies suggest that there 
is a risk of serotonin syndrome with the concomitant ingestion of 
ayahuasca and antidepressants or other pro-serotonergic drugs, but 
more studies are needed in this area64,65. Other area of research focus 
should be the health contraindications to ayahuasca use. For instance, 
there is no information regarding the possible effects of ayahuasca in 
people with cardiovascular disease, and more research is needed on 
the cardiovascular effects of chronic ayahuasca intake.
There is also a lack of information regarding the possible 
effects of ayahuasca (harmful or beneficial) on people suffering 
neuropsychiatric diseases such as epilepsy, Parkinson’s disease 
and Alzheimer’s disease, or in those with autoimmune and 
neuroinflammatory diseases11,12. In the specific case of Parkinson’s 
disease, early evidence shows that harmine was used to treat 
symptoms of this disease in the late 1920s and early 1930s66. Evidence 
supporting this use has been recently reported in preclinical studies 
using B. caapi extract67 and also in a double-blind, randomized, 
placebo-controlled trial in which B. caapi extracts improved motor 
function in these patients68. The benefits obtained by the use of B. 
caapi were more significant than the results showed by harmine 
alone, which may suggest and “entourage” effect that should also be 
considered in ayahuasca research. Probably, the different alkaloids 
present in the vine “cooperate” to produce a final effect more effective 
than the different compounds in their pure form and separately. 
Therefore, more research in this area is needed.
Recent reports suggest the possible role of harmine in 
neurogenesis69. Furthermore, it is known that DMT act as an agonist 
at 5-HT1A receptors8,70. The activation of 5-H1A receptors may be in 
the basis of neurogenesis in the hippocampus and in the prefrontal 
cortex and its activation seems to be in the basis of the antidepressant 
effects of antidepressive drugs71.
Regarding adverse effects, a recent study from the United States 
showed that 538 calls related to ayahuasca use were reported between 
Table 4. Main adverse reactions associated with ayahuasca intake
Physical symptoms (acute)16,18-21








Anxiety, panic, and fear
Psychotic symptoms (less common)
Psychological symptoms (prolonged)23,59
Psychotic reactions (rare)
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September 1, 2005 to September 1, 2015 to the American Association 
of Poison Controls Centers’ (AAPCC) National Poison Data System 
(NPDS)72. Most cases involved acute intoxication in young male 
adults and were considered of major or moderate clinical significance, 
and included symptoms such as hallucinations, tachycardia, agitation, 
hypertension, mydriasis and vomiting. Importantly, 28 cases required 
endotracheal intubation, and there were four cases of cardiac arrest, 
seven of respiratory arrest, 12 of seizures, and three fatalities. 
Unfortunately, there is no detailed description of the cases, which 
makes it difficult to affirm that all of them were directly caused only by 
ayahuasca. Indeed, some of the mediatic and scientific descriptions of 
severe intoxications supposedly caused by ayahuasca could possibly 
be referring to the result of a combination of several factors, including 
the addition of more toxic plants to the ayahuasca preparation (such 
as some Brugmansia species) and the previous physical and mental 
health of the person drinking ayahuasca, including the medications 
being used by this person73. Moreover, it appears that such cases seem 
to be more common on countries where ayahuasca is not part of the 
local religious traditions (such as the United States), and seem to 
be less common in countries where ayahuasca is part of the culture 
(such as Brazil, Peru and Colombia)72,73. Furthermore, several of 
the incidents reported in South American countries involved North 
Americans or Europeans72,73. Maybe the tourism around ayahuasca 
is bringing to Amazonian countries foreigners with health problems 
that are not always screened by all people organizing ayahuasca 
rituals, and maybe some people organizing these rituals outside South 
America are serving ayahuasca to people that they do not know their 
previous health condition. 
Regarding the incidence of prolonged dysphoric reactions 
to ayahuasca use, characterized by anxiety, panic, or psychotic 
symptoms, the research conducted so far in this area is limited to 
anecdotal evidence, case reports and case series, and should be 
further developed22,23,59. It seems that only a minority of individuals 
suffer such reactions, and in many of those cases these individuals 
had personal or family histories of psychiatric disorders22,23,59. 
This kind of reaction have not been reported in experimental and 
clinical studies with ayahuasca21,23,36 and are also rare in the case of 
controlled administration of other hallucinogens36,52,53. It seems that 
carefully screening the volunteers to exclude individuals with some 
predisposition to psychotic disorders is an important measure to 
reduce the possibility of the occurrence of such cases23,52,53. Future 
research should focus on trying to better identity who are those 
individuals more prone to suffer a prolonged dysphoric or psychotic 
reaction to ayahuasca.  
In the last 20 years, an increasing number of neuroimaging 
studies involving the administration of classic hallucinogens 
to humans has been conducted, and this area is still in full 
development25,26. Compared to other hallucinogens such as 
psilocybin, neuroimaging studies with ayahuasca are still small in 
number, but this picture should change in the near future since there 
is an increasing number of studies with ayahuasca20,25,26,32-34,42. Areas 
that are currently being investigated and that should be further 
explored include the study of the neural basis of the antidepressant 
and anxiolytic effects of ayahuasca and its effects on the default 
mode network (DMN), a network whose alteration may be related 
to diseases that go from autism to schizophrenia or depression, and 
on brain areas that regulate emotions, memory, and higher cognition 
including self-awareness and introspection20,25,26,32-34,42. Moreover, 
recent uncontrolled studies suggest that ayahuasca may increase 
mindfulness capacities and creativity74-76 Thus, studies with improved 
methodologies that include controlled designs and neuroimaging 
could improve our understanding of this possible effects of ayahuasca 
and the possible association between them and the therapeutic 
properties of ayahuasca.
Finally, another area that should be better investigated is 
related to the individual effects of DMT and the β-carbolines. 
Indeed, recent studies suggest that endogenous DMT, through 
the sigma-1 receptor, could be involved in physiological processes 
such as immunity and inflammatory responses, and also tissue 
protection and regeneration11,12. The fact is that we still do 
not know what DMT is doing in our bodies, so this is a very 
interesting topic to further investigate9,10. Moreover, preclinical 
studies suggest that DMT and the β-carbolines have not only 
antidepressive, anxiolytic, and antiaddictive proprieties39,40, 
but also neuroprotective and neurotrophic potentials69,77-79. For 
instance, a recent neuropsychological study in ayahuasca user 
suggested that ayahuasca may indeed improve cognition and have 
“nootropic” effect80. However, although the preclinical data on 
antidepressive, anxiolytic, and antiaddictive potentials of ayahuasca 
and its alkaloids has been replicated to some extend in preliminary 
observational and clinical studies in humans, with the exception of 
the neuropsychological study just commented, studies on possible 
neuroprotective and neurotrophic effects are still on the basic level. 
Future studies should further explore this area.
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